Akebia Therapeutics (AKBA) Competitors $2.85 -0.10 (-3.39%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$2.88 +0.03 (+1.23%) As of 05:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKBA vs. KNSA, APLS, MOR, GMTX, IMVT, HCM, OGN, MLYS, ALVO, and TARSShould you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Kiniksa Pharmaceuticals International (KNSA), Apellis Pharmaceuticals (APLS), MorphoSys (MOR), Gemini Therapeutics (GMTX), Immunovant (IMVT), HUTCHMED (HCM), Organon & Co. (OGN), Mineralys Therapeutics (MLYS), Alvotech (ALVO), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. Akebia Therapeutics vs. Its Competitors Kiniksa Pharmaceuticals International Apellis Pharmaceuticals MorphoSys Gemini Therapeutics Immunovant HUTCHMED Organon & Co. Mineralys Therapeutics Alvotech Tarsus Pharmaceuticals Akebia Therapeutics (NASDAQ:AKBA) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment. Which has better earnings and valuation, AKBA or KNSA? Kiniksa Pharmaceuticals International has higher revenue and earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkebia Therapeutics$160.18M4.72-$69.41M-$0.17-16.76Kiniksa Pharmaceuticals International$423.24M6.71-$43.19M$0.04957.75 Is AKBA or KNSA more profitable? Kiniksa Pharmaceuticals International has a net margin of 0.90% compared to Akebia Therapeutics' net margin of -17.91%. Kiniksa Pharmaceuticals International's return on equity of 1.05% beat Akebia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akebia Therapeutics-17.91% N/A -13.47% Kiniksa Pharmaceuticals International 0.90%1.05%0.80% Do insiders & institutionals have more ownership in AKBA or KNSA? 33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 3.0% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 53.5% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, AKBA or KNSA? Akebia Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Does the media prefer AKBA or KNSA? In the previous week, Kiniksa Pharmaceuticals International had 5 more articles in the media than Akebia Therapeutics. MarketBeat recorded 7 mentions for Kiniksa Pharmaceuticals International and 2 mentions for Akebia Therapeutics. Kiniksa Pharmaceuticals International's average media sentiment score of 0.37 beat Akebia Therapeutics' score of 0.15 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kiniksa Pharmaceuticals International 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate AKBA or KNSA? Akebia Therapeutics currently has a consensus target price of $6.75, suggesting a potential upside of 136.84%. Kiniksa Pharmaceuticals International has a consensus target price of $44.29, suggesting a potential upside of 15.60%. Given Akebia Therapeutics' higher possible upside, equities research analysts clearly believe Akebia Therapeutics is more favorable than Kiniksa Pharmaceuticals International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71Kiniksa Pharmaceuticals International 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 SummaryKiniksa Pharmaceuticals International beats Akebia Therapeutics on 14 of the 17 factors compared between the two stocks. Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKBA vs. The Competition Export to ExcelMetricAkebia TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$782.18M$2.62B$6.09B$10.54BDividend YieldN/A56.71%5.69%4.71%P/E Ratio-16.7623.6985.3527.60Price / Sales4.72556.23539.78202.41Price / CashN/A173.2337.9261.55Price / Book-12.395.5313.016.76Net Income-$69.41M$32.78M$3.30B$275.88M7 Day Performance5.17%5.82%4.34%2.81%1 Month Performance-5.00%13.16%9.49%9.24%1 Year Performance122.66%1.69%84.83%35.42% Akebia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKBAAkebia Therapeutics3.4718 of 5 stars$2.85-3.4%$6.75+136.8%+115.9%$782.18M$160.18M-16.76430Analyst ForecastKNSAKiniksa Pharmaceuticals International3.649 of 5 stars$38.77+6.2%$44.29+14.2%+56.6%$2.87B$423.24M969.49220Analyst DowngradeAPLSApellis Pharmaceuticals4.0659 of 5 stars$22.65+1.3%$33.29+47.0%-9.1%$2.86B$781.37M-12.44770Analyst ForecastMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$65.55+4.9%N/A+43.4%$2.84BN/A-65.5530IMVTImmunovant1.8768 of 5 stars$16.06-1.0%$33.60+109.2%-45.7%$2.80BN/A-5.64120HCMHUTCHMED2.4168 of 5 stars$15.66+0.1%$20.88+33.3%-20.5%$2.73B$630.20M0.001,811Analyst ForecastOGNOrganon & Co.4.7515 of 5 stars$10.35+1.3%$17.33+67.6%-43.4%$2.69B$6.40B3.854,000Analyst ForecastMLYSMineralys Therapeutics2.7637 of 5 stars$39.35-1.6%$43.50+10.5%+175.7%$2.61BN/A-11.0528Positive NewsAnalyst ForecastHigh Trading VolumeALVOAlvotech3.2774 of 5 stars$8.40+0.7%$14.00+66.7%-32.5%$2.53B$491.98M36.521,032Analyst ForecastGap UpTARSTarsus Pharmaceuticals0.7744 of 5 stars$58.08+3.2%$66.67+14.8%+105.1%$2.45B$182.95M-24.9350Analyst Forecast Related Companies and Tools Related Companies KNSA Alternatives APLS Alternatives MOR Alternatives GMTX Alternatives IMVT Alternatives HCM Alternatives OGN Alternatives MLYS Alternatives ALVO Alternatives TARS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKBA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
